Infliximab treatment for refractory Kawasaki disease in Korean children

Korean Circulation Journal

Volumn 40, Issue 7, 2010, Pages 334-338

  Song, Min Seob ^a   Lee, Sang Bum ^b   Sohn, Sejung ^c   Oh, Jin Hee ^d   Yoon, Kyung Lim ^e   Han, Ji Whan ^d   Kim, Chul Ho ^a  

^a Inje University College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

Author keywords

Infliximab; Kawasaki disease

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB;

ACUTE HEPATITIS; ADOLESCENT; ARTICLE; CHILD; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; FEMALE; FEVER; HUMAN; INFANT; KOREA; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; TREATMENT RESPONSE;

EID: 77955479123     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.7.334     Document Type: Article

References (30)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
2. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
3. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
4. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
5. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8.
6. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.
7. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006;33:803-9.
8. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
9. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004,110:2747-71.
10. Weiss JE, Eberhard A, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
11. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare; 1984.
12. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9.
13. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44.
14. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4.
15. Nachiappan J, May M, Hawker RE, Hong P. Resistant Kawasaki disease. J Paediatr Child Health 2004;40:576-8.
16. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
17. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
18. Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9.
19. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
20. Wright DA, Newburger JW, Baker A, Sumdel RP. Treatment of immune-globulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
21. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7.
22. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6.
23. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
24. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMI-CADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
25. Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009;65:696-701.
26. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
27. Shin JU, Cho HK, Shin MS. Elevated tumor necrosis factor-alpha in stable angina pectoris. Korean Circ J 2000;30:861-6.
28. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
29. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
30. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.